• JAMA · Aug 2019

    Practice Guideline

    Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement.

    • US Preventive Services Task Force, Douglas K Owens, Karina W Davidson, Alex H Krist, Michael J Barry, Michael Cabana, Aaron B Caughey, Susan J Curry, Chyke A Doubeni, John W Epling, Martha Kubik, C Seth La... more ndefeld, Carol M Mangione, Lori Pbert, Michael Silverstein, Melissa A Simon, Chien-Wen Tseng, and John B Wong. less
    • Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
    • JAMA. 2019 Aug 6; 322 (5): 438-444.

    ImportancePancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. Although its incidence is low, pancreatic cancer is the third most common cause of cancer death in the United States. Because of the increasing incidence of pancreatic cancer, along with improvements in early detection and treatment of other types of cancer, it is estimated that pancreatic cancer may soon become the second-leading cause of cancer death in the United States.ObjectiveTo update the 2004 US Preventive Services Task Force (USPSTF) recommendation on screening for pancreatic cancer.Evidence ReviewThe USPSTF reviewed the evidence on the benefits and harms of screening for pancreatic cancer, the diagnostic accuracy of screening tests for pancreatic cancer, and the benefits and harms of treatment of screen-detected or asymptomatic pancreatic cancer.FindingsThe USPSTF found no evidence that screening for pancreatic cancer or treatment of screen-detected pancreatic cancer improves disease-specific morbidity or mortality, or all-cause mortality. The USPSTF found adequate evidence that the magnitude of the benefits of screening for pancreatic cancer in asymptomatic adults can be bounded as no greater than small. The USPSTF found adequate evidence that the magnitude of the harms of screening for pancreatic cancer and treatment of screen-detected pancreatic cancer can be bounded as at least moderate. The USPSTF reaffirms its previous conclusion that the potential benefits of screening for pancreatic cancer in asymptomatic adults do not outweigh the potential harms.Conclusions And RecommendationThe USPSTF recommends against screening for pancreatic cancer in asymptomatic adults. (D recommendation).

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…